IAM Market moves to the IAM platform
The global marketplace allows IP rights owners to present assets for license, sale or transfer to our unique audience of senior decision takers and deal makers
The global marketplace allows IP rights owners to present assets for license, sale or transfer to our unique audience of senior decision takers and deal makers
“In 2022 we chose to wind down our wireless patent pools. Consistent with that decision, we are also exiting the Alium partnership,” states Via LA President Heath Hoglund
Although heavy reliance on government-backed initiatives creates uncertain future for IP holders
Selling revenue streams is an increasingly important way of monetising pharma innovations
16 November 2022
An over-arching theme during an IAM event was the key importance of relationships, trust and empathy between parties when deals are getting done
11 November 2022
Strategic review of the licensing business nears a year in motion with no news on potential divestment announced
10 November 2022
Behzad Khosrowshahi, CEO of DRI Healthcare Trust, looks at recent deals the firm has done, explains what makes a transaction attractive and how to get one over the line
04 November 2022
As the sovereign patent fund closes down, CEO Didier Patry shares his thoughts with IAM readers on the organisation’s work over the past decade
03 November 2022
A broad range of subjects and talking points - including a plenary address from JPO Commissioner Koichi Hamano - kept the 400+ delegates engaged as the event got underway in Tokyo
01 November 2022
The series of missteps and errors in the Canadian company’s struggling patent portfolio sale offers a cautionary tale to any IP owner emulating this in future
29 October 2022
The company’s high value was produced by a series of innovative patent transactions
27 October 2022
It is crucial that a buyer or seller of a company does not overlook trademarks and brands in business acquisitions, or any red flags in that area. Luckily, there are solutions to overcome such complexities.
26 October 2022
Success at the USPTO clinched a premium-price acquisition for the oncology innovator
25 October 2022
Unlock unlimited access to all IAM content